



Venus Medtech (Hangzhou) Inc.
杭州啓明醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(於中華人民共和國註冊成立的股份有限公司)
(Stock Code 股份代號: 2500)

April 3, 2024

Dear registered shareholder(s),

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023 and the Articles of Association of Venus Medtech (Hangzhou) Inc. (the "Company"), the Company is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.venusmedtech.com and the HKEXnews website at www.hkxnews.hk in place of printed copies.

Solicitation of electronic contact details

The Company will send the Actionable Corporate Communications* to its Shareholders individually in electronic form by email. To ensure timely receipt of the Actionable Corporate Communications*, the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "Reply Form"). Alternatively, you may sign and return the Reply Form to the Company's Hong Kong H share registrar (the "H Share Registrar"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive the duly completed and signed Reply Form or any response in writing indicating any objection from you by April 18, 2024, and until you inform the H Share Registrar, you are deemed to have consented to read all future Corporate Communications published on the website of the Company at www.venusmedtech.com (the "Website Version"), and a notification of the publication of the Corporate Communications on the Company's website will be sent to you in the future.

If you elect to receive the Website Version of future Corporate Communications, you are requested to provide an email address in the Reply Form for the purpose of receiving all future Actionable Corporate Communications* in electronic form from the Company. If no valid and functional email address is provided by you in the Reply Form or if you are otherwise deemed to have consented to receive the Website Version of future Corporate Communications, the Company will send to you by post at your address as appearing in the Company's register of members maintained by the H Share Registrar, (i) a notification letter for the publication of Corporate Communications on the website of the Company and (ii) all future Actionable Corporate Communications in printed form, until such time when you have provided a valid and a functional email address to the H Share Registrar for receiving the same.

If you want to receive future Corporate Communications in printed form, please complete the Reply Form on the reverse side and send it to the H Share Registrar or send an email to venusmedtech.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the H Share Registrar at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

Yours faithfully,
By order of the Board
Venus Medtech (Hangzhou) Inc.
Mr. Lim Hou-Sen (Lin Haosheng)
Executive Director

* Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東：

以電子方式發布公司通訊之安排

根據香港聯合交易所有限公司證券上市規則第 2.07 條已於 2023 年 12 月 31 日起生效的擴大無紙化制度及以電子方式發布公司通訊規定下，以及杭州啓明醫療器械股份有限公司（「公司」）的組織章程細則，公司謹此通知 閣下，公司已採用以電子方式發布公司通訊（「公司通訊」）之安排，該公司通訊是指公司向任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件，包括但不限於(a) 董事會報告、年度帳目以及審計報告副本以及（如適用）財務摘要報告；(b) 中期報告及其中期報告摘要（如適用）；(c) 會議通知；(d) 上市文件；(e) 通函和 (f) 代表委任表格。

請注意，所有未來公司通訊的英文版和中文版將在公司網站 www.venusmedtech.com 和披露易網站 www.hkxnews.hk 上提供，以代替印刷本。

徵集電子聯絡資料

公司將以電子通訊方式（通過電子郵件）向股東個別地發送可供採取行動的公司通訊*。為確保及時收到可供採取行動的公司通訊*，公司建議 閣下透過掃描本函背頁之回條（「回條」）上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。或者， 閣下也可以簽署回條並交回公司的 H 股股份過戶登記處（「H 股股份過戶處」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

倘若公司於二零二四年四月十八日之前尚未收到 閣下已填妥並簽署之回條或表示反對之任何書面回覆， 閣下將被視為已同意瀏覽於本公司網站 www.venusmedtech.com（「網上版本」）上的所有公司通訊，而公司日後將向 閣下發送已在公司網站登載的公司通訊之通知。

如 閣下選擇接收日後公司通訊的網上版本， 閣下需要在回條中提供電郵地址，以便接收公司日後以電子形式發布的所有可供採取行動的公司通訊*。若 閣下在回條中沒有提供有效且可用的電郵地址，或 閣下被視為已同意接收日後公司通訊的網上版本，公司將根據 H 股股份過戶處所存置的股東名冊上所示的地址透過郵寄方式向 閣下發送 (i) 在公司網站上發布公司通訊的通知函及 (ii) 所有日後可供採取行動的公司通訊的印刷本，直至 閣下向股份過戶登記處提供有效且可用的電郵地址以接收該等公司通訊。

若 閣下希望收取日後公司通訊之印刷本，請填妥回條或發送電子郵件至 venusmedtech.ecom@computershare.com.hk，並註明 閣下的姓名、地址以及收取公司通訊印刷本的要求。請注意，收取未來公司通訊印刷本之指示由收悉 閣下指示當日起計一年內有效，此後將過期。

如 閣下對本函件有任何疑問，請於辦公時間星期一至五（香港公眾假期除外）上午 9 時正至下午 6 時正（香港時間）期間致電 H 股股份過戶處（852）2862 8688 查詢。

承董事會命
杭州啓明醫療器械股份有限公司
執行董事
林浩昇先生
謹啟

二零二四年四月三日

*「可供採取行動的公司通訊」指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。

